Description: Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Its principal products include Plavix for protection against fatal or non-fatal heart attack or stroke; Avapro/Avalide for the treatment of hypertension and diabetic nephropathy; Eliquis to prevent and treat venous thromboembolic disorders and stroke prevention in atrial fibrillation; Abilify, an agent for adult patients with schizophrenia, bipolar mania disorder, and depressive disorder; and Reyataz and Sustiva to treat human immunodeficiency virus. The company's products also include Baraclude, an inhibitor of hepatitis B virus; Erbitux to target and block the epidermal growth factor receptor; Sprycel for treatment of chronic myeloid leukemia in adults; Yervoy to treat metastatic melanoma; Orencia to treat adult patients with moderate to severe rheumatoid arthritis; Nulojix to prevent kidney transplant rejection; Onglyza/Kombiglyze, Byetta, and Bydureon to treat type 2 diabetes; and Forxiga for the treatment of diabetes. Its products under Phase III clinical trials include Asunaprevir and Daclatasvir, which are oral small molecule to treat hepatitis C virus infection; Peginterferon lambda, a novel type 3 interferon for hepatitis C virus infection; Elotuzumab for multiple myeloma; and Nivolumab, an anticancer treatment, as well as products under the registrational process comprises Metreleptin for the treatment of lipodystrophy. The company sells its products to wholesalers, as well as directly to distributors, retailers, hospitals, clinics, government agencies, and pharmacies. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Home Page: www.bms.com
BMY Technical Analysis
430 East 29th Street
New York,
NY
10016
United States
Phone:
212 546 4000
Officers
| Name | Title |
|---|---|
| Dr. Giovanni Caforio M.D. | Chairman & CEO |
| Mr. David V. Elkins | Exec. VP & CFO |
| Ms. Sandra Leung Esq. | Exec. VP & Gen. Counsel |
| Dr. Christopher S. Boerner | Exec. VP & Chief Commercialization Officer |
| Mr. Rupert Vessey BCH, BM, DPHIL, M.A. | Exec. VP and Pres of Research & Early Devel. |
| Mr. Greg Meyers | Exec. VP and Chief Digital & Technology Officer |
| Mr. Timothy Power | VP & Head of Investor Relations |
| Ms. Cari Gallman | Sr. VP & Chief Compliance and Ethics Officer |
| Ms. Ann M. Powell Judge | Exec. VP & Chief HR Officer |
| Mr. Jitendra Tyagi | Head of US Drug Makers - India |
Exchange: NYSE
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 9.9701 |
|---|---|
| Trailing PE: | 23.1303 |
| Price-to-Book MRQ: | 5.1301 |
| Price-to-Sales TTM: | 3.4118 |
| IPO Date: | 1972-01-01 |
| Fiscal Year End: | December |
| Full Time Employees: | 32200 |